analyzed fecal microbiome samples from 43 melanoma patients who were undergoing PD-1 blockade immunotherapy, and they found responding patients have a higher alpha diversity of bacteria than the non-responders, they also found that patients with higher alpha diversity in their fecal samples had significantly prolonged PFS than the patients in low alpha diversity (17). The gene discussed is PDCD1; the disease is melanoma.